Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
OTTAWA, ON, May 11, 2021 /CNW/ - CSL Behring Canada announced that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), is now available in all of Canada. HAEGARDA is a subcutaneous C1 esterase...
CSL Behring Canada announced that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), is now available in the province of Québec. HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy ...
The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has renewed its commitment as a Visionary Corporate Partner with WFH for...
CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) clinical trial and the first patient enrollment. The...
CSL Behring is pleased to announce that on March 31st, 2017 Berinert (C1 Esterase Inhibitor, Human) was approved by Heath Canada for Pediatric Hereditary Angioedema (HAE). "HAE is an unpredictable...
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the...
Global biotherapeutics leader CSL Behring announced that Health Canada has approved AFSTYLA [Antihemophilic Factor VIII (Recombinant), SingleChain], its novel long-lasting recombinant factor VIII...
CSL Behring today presented data from Phase III studies evaluating the efficacy and long-term safety of its investigational long-acting fusion protein linking recombinant coagulation factor IX with...
CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain (rVIII-SingleChain) in adolescents and adults...
CSL Behring announced today it will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015...
CSL Behring announced today that Health Canada has approved a new, low-volume presentation size for the existing indications of Berinert®, a human plasma-derived, pasteurized and nanofiltered...
CSL Behring announced today that the company has named five recipients of the 2015 CSL Behring Professor Heimburger Award for coagulation research. Now in its eighth year, the global awards program...
In recognition of World Hemophilia Day April 17, the World Federation of Hemophilia (WFH) and CSL Behring announced today that CSL Behring has once again committed to donating bleeding disorder...
CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting...
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion...
CSL Behring announced today it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the marketing authorization of its long-acting fusion...
Third annual awareness day shines a light on rare, potentially life-threatening condition KING OF PRUSSIA, Pa., May 14, 2014 /CNW/ - As a Diamond Sponsor of HAE Day on May 16, 2014, CSL Behring is...
TOKYO, Sept. 27, 2013 /CNW/ - CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra® (Immune Globulin Subcutaneous [Human]) for the...
Results of Part 1 of the study will be presented at the 2013 International Society on Thrombosis and Haemostasis in Amsterdam, Netherlands on 2 July, 2013 KING OF PRUSSIA, Pa., June 4, 2013 /CNW/ -...
Data presented at biennial ESID meeting reveal pharmacoeconomic benefits of switching from IVIG to SCIg in primary immunodeficiency FLORENCE, Italy, Oct. 4, 2012 /CNW/ - Analysis using a new economic ...
Subcutaneous therapy maintains high serum immunoglobulin levels, provides passive immunity and improves quality of life following conversion from intravenous treatment FLORENCE, Italy, Oct. 4, 2012...
GLASGOW, Scotland, Sept. 7, 2012 /CNW/ - The German Society for Immunology (DGfI) has awarded its 2012 Avery-Landsteiner Prize to Alain Fischer, M.D., Ph.D., of Paris, France, for his milestone...
Current VWD treatment strategies found potentially insufficient in postpartum period; further study of benefits of prophylaxis treatment needed KING OF PRUSSIA, Pa., July 11, 2012 /CNW/ - Findings of ...
Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor KING OF PRUSSIA, Pa. and MARBURG, Germany, May 3, 2012...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.